GSK plc (LON:GSK) Receives GBX 2,034.29 Consensus PT from Analysts

GSK plc (LON:GSK – Get Free Report) has received a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,034.29.

Several brokerages recently weighed in on GSK. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,900 price target on shares of GSK in a report on Monday, June 8th. Citigroup decreased their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, March 25th.

Get GSK alerts:

View Our Latest Stock Analysis on GSK

Insider Buying and Selling

In related news, insider Jonathan Symonds purchased 1,550 shares of the firm’s stock in a transaction that occurred on Friday, June 19th. The stock was purchased at an average cost of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Jeannie Lee purchased 802 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Insiders bought 7,630 shares of company stock valued at $21,357,859 in the last ninety days. Company insiders own 0.31% of the company’s stock.

GSK Price Performance

GSK stock opened at GBX 1,981 on Monday. The company has a market capitalization of £79.45 billion, a P/E ratio of 13.94, a PEG ratio of 1.24 and a beta of 0.29. GSK has a twelve month low of GBX 1,288.61 and a twelve month high of GBX 2,282. The business has a 50 day simple moving average of GBX 1,939.56 and a 200-day simple moving average of GBX 1,970.43. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74.

GSK (LON:GSK – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The business had revenue of GBX 762.90 billion during the quarter. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current year.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

See Also

• Five stocks we like better than GSK
• As Stablecoins Keep Growing, These 2 Stocks Benefit
• Apple Just Handed These 4 Memory Stocks Their Best News of the Year
• Costco’s Secret Growth Engine May Be Running Out of Gas
• Why Alphabet’s Pullback May Be an Opportunity in Disguise

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.